{
    "symbol": "DCGO",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-14 08:50:24",
    "content": " For the quarter, we generated total revenue of $118 million, representing growth of 137% over the first quarter a year ago. Revenue growth was again driven by a mobile health division, which generated revenue of $90.1 million, an increase of 193% over 30.7 million in the first quarter of 2021. Total revenue for the first quarter of 2022 amounted 217.9 million, representing growth of 137% as compared to the 49.7 million reported for the first quarter of 2021. Mobile Health revenue for the first quarter of 2022 amounted to 90.1 million as compared to 3.7 million in Q1 of '21, up approximately 193%. It's important to note that excluding COVID testing related revenue from Q1 of both years, total Q1 revenues to increase approximately 2.7 times year-over-year, increasing from approximately 29 million in Q1 '21 to approximately 80 million in Q1 2022 strong momentum in our core mobile health, business and consistent growth in our cancer patient segment. Total gross margin percentage during Q1 '21 amounted to 33.8% as compared to 28.2% during the prior year, the 5.7% increase in the total gross margin but driven by the Mobile Health segment, via gross margins increased from 30.9% during Q1 last year, to 37.3% during our previous quarter this year. We confirm the guidance we provided and anticipate 2022 revenue to be approximately $400 million to $420 million, representing growth of 27% to 32% over '21. After Q2, company will no longer track over testing revenue as a separate number, since it is becoming a much more percentage of revenues and COVID testing services are invaded with the mobile health contracts, as just another service."
}